ClinicalTrials.Veeva

Menu

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis (EDELWEISS)

O

ObsEva

Status and phase

Completed
Phase 2

Conditions

Endometriosis

Treatments

Drug: OBE2109
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02778399
15-OBE2109-001

Details and patient eligibility

About

The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.

Full description

The study is a prospective, dose-finding, randomized, parallel group, double-blind, placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the treatment of 330 women with moderate-to-severe endometriosis associated pain.

Subject will be randomized to one of 6 treatment groups in a 1:1:1:1:1:1 ratio (1 placebo group, 5 dose groups with different dosage/regimen).

Eligible subjects will be offered the opportunity to continue treatment with OBE2109 in an extension phase. Subjects who do not continue in the extension will enter the treatment-free follow-up phase of the study.

Enrollment

328 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • The subject must have had her most recent surgical and - if available - histological, diagnosis of pelvic endometriosis up to 10 years before screening.
  • The subject has moderate to severe endometriosis-associated pain during the screening period.
  • The subject has regular menstrual cycles.
  • The subject has a BMI ≥ 18 kg/m2 at the screening visit.

Key Exclusion Criteria:

  • The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • The subject had an interventional surgery for endometriosis performed within a period of 60 days before screening.
  • The subject did not respond to prior treatment with gonadotropin releasing hormone (GnRH) agonists or GnRH antagonists for endometriosis.
  • The subject has a history of, or known osteoporosis or other metabolic bone disease.
  • The subject has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic / therapy, or that would interfere with the assessment of endometriosis related pain.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

328 participants in 6 patient groups, including a placebo group

OBE2109 50 mg
Experimental group
Treatment:
Drug: OBE2109
OBE2109 75mg fixed dose (FD)
Experimental group
Treatment:
Drug: OBE2109
OBE2109 75mg titrated dose (TD)
Experimental group
Treatment:
Drug: OBE2109
OBE2109 100mg
Experimental group
Treatment:
Drug: OBE2109
OBE2109 200 mg
Experimental group
Treatment:
Drug: OBE2109
Placebo / OBE2109 100mg
Placebo Comparator group
Description:
Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.
Treatment:
Drug: OBE2109
Drug: Placebo

Trial documents
1

Trial contacts and locations

86

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems